Pharmaceutical supply chains could use shared blockchain records to trace the movement of medicines and enable more targeted recalls, according to an explainer published by the Chicago Star. The article outlines how a shared ledger might connect records currently held separately by manufacturers, distributors and pharmacies.

The proposal centers on tracking, not on guaranteeing medicine quality. While blockchain can preserve a recorded product history, it cannot establish that the information was accurate when it was first entered.

Pharmaceutical Supply Chains Need Connected Records

The explainer describes a distribution system that spans multiple stakeholder groups and, frequently, multiple countries. Participants include manufacturers, distributors, wholesalers, pharmacies and healthcare providers.

Tracking products across these organizations can become difficult when a batch's authenticity is called into question. Recalls also require participants to determine where affected medicines traveled and who received them.

Under the blockchain approach described, each participant would record distribution events on shared infrastructure. That would replace the current reliance on separately held histories when investigators need to reconstruct a product's journey.

The explainer cites World Health Organization estimates that 1 in 10 medicines in low- to middle-income countries are falsified or substandard, along with estimated annual spending of around $30.5 billion USD on products. Those figures give the tracing debate its public-health stakes: falsified or substandard products are difficult to chase out of circulation when no single participant holds a complete record of where they went.

The discussion sits within blockchain's broader use for recording information. Related coverage examines AI data registry migration, a separate effort involving data provenance and rights.

A Shared History Could Follow Each Medicine Batch

According to the explainer, the process would begin when a manufacturer records a batch leaving production. A distributor would then log its receipt, followed by transfers to the wholesaler and the pharmacy.

A unique identifier would connect each product with its recorded events, and that history would continue until the medicine was sold.

Investigators could consult the shared record instead of comparing information across separate databases. The source describes blockchain ledgers as highly resistant to tampering with events that have already been recorded.

That resistance has a specific limit: it concerns the history after entry. It does not prevent someone from entering fraudulent or incorrect information at the beginning.

Digital record integrity is also the subject of separate coverage about malware hidden in blockchain transactions, which examines a different security problem involving permanent ledgers.

Physical Checks and Recall Planning Still Matter

The source says physical verification, appropriate identification technologies and trusted organizations remain important. An incorrectly marked product would not become authentic simply because its record entered a blockchain.

For pharmaceutical supply chains, the potential benefit is a clearer account of handling and storage, one that regulators, manufacturers and distributors could consult when something goes wrong.

The explainer connects electronic tracing with the FDA's Drug Supply Chain Security Act framework, which aims to improve participants' ability to identify and trace products. Enacted in the United States in 2013, that law centers on identifying and tracing prescription drugs as they move through distribution — the same product-level anchor the explainer's proposed ledger would rely on.

If a manufacturer found a tainted batch, accurately recorded events could help locate its recipients. Pharmacies, wholesalers and healthcare providers could then be contacted about the specific products involved.

Such targeting could make recalls faster and more precise, the source argues, though those benefits depend on accurate event records rather than blockchain technology alone. Another discussion of operational infrastructure appears in coverage of blockchain validator services.

The explainer lays out a model rather than a deployed system, so the development to watch is whether any network of manufacturers, distributors and pharmacies moves from describing a shared medicine ledger to operating one.

The practical distinction remains between preserving records and verifying goods. Shared histories could assist tracing, while physical checks and reliable initial information remain necessary for establishing medicine authenticity.